ProShares - ProShares VIX Mid-Term Futures ETF (VIXM) falls 0.99% in Active Trading on January 14

Equities Staff  |

ProShares Trust - ProShares VIX Mid-Term Futures ETF (CBOE: VIXM) shares fell 0.99%, or $0.3 per share, to close Friday at $29.99. After opening the day at $30.76, shares of ProShares - ProShares VIX Mid-Term Futures ETF fluctuated between $30.76 and $29.88. 79,030 shares traded hands an increase from their 30 day average of 73,489. Friday's activity brought ProShares - ProShares VIX Mid-Term Futures ETF’s market cap to $112,084,626.

Visit ProShares Trust - ProShares VIX Mid-Term Futures ETF’s profile for more information.

About CBOE Global Markets

CBOE operates the largest options exchange and the third largest stock exchange in the U.S. CBOE runs a total of four separate stock exchanges that it acquired through the acquisition of Bats Global Markets in 2017. Collectively, these exchanges account for about 17% of total US equities volume.

To get more information on ProShares Trust - ProShares VIX Mid-Term Futures ETF and to follow the company’s latest updates, you can visit the company’s profile page here: ProShares Trust - ProShares VIX Mid-Term Futures ETF’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

Algoma Steel Upgrades Power Plant in Transition to Green Steelmaking
Insulet Gets FDA Clearance for Omnipod 5 Automated Insulin Delivery System
Russell 2000 Enters Bear Market Territory for First Time in Nearly Two Years
TG Therapeutics Tumbles 40% on Partial Clinical Trial Hold
Huawei Says Carrier Business Stable as Revenues Decline: Jeff Kagan
Time To Reconsider Galapagos as New CEO Paul Stoffels Named
Global Politics Could Drive Extreme Market Volatility in 2022
Stock Stage Sharp Monday Afternoon Rally To Erase Morning Losses

Market Movers

Sponsored Financial Content